Purdue Pharmaceuticals, L.P.
Headquarters
One Stamford Forum
Stamford
Connecticut
06901-3431
United States
Tel: 203-588-8000
Fax: 203-588-8850
Website: http://www.purduepharma.com/
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
229 articles with Purdue Pharmaceuticals, L.P.
-
Arguments regarding the Purdue Pharma opioid settlement continue to be heard in court, Natera battles a class-action lawsuit, Walgreens is involved in a public nuisance suit and more.
-
McKinsey & Company is under fire for allegedly allowing its employees to work simultaneously for big pharma companies and serve as consultants for the U.S. Food and Drug Administration.
-
As Martin Shkreli, Elizabeth Holmes and Sunny Balwani, and the Purdue bankruptcy deal play out, there is even more drama beyond the stories–a failure to pay legal fees.
-
Money on the Move: March 23-29
3/30/2022
This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding. -
Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.
-
Purdue Pharma L.P. to Provide Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal in Emergency Medicine Settings
3/17/2022
Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to assess opioid overdose reversal in Emergency Department (ED) and Emergency Medical Service (EMS) settings.
-
Opioid Overdose Victims Confront Purdue Pharma’s Sackler Family Following Latest Settlement
3/11/2022
More than two dozen people were given the opportunity to confront members of the Sackler family in a virtual environment and share the impactful pain opioid addiction caused their families. -
Members of the Sackler family will dedicate at least $5.5 billion plus 100% of the debtors' assets to opioid abatement and victims.
-
The FDA's decision to approve Purdue's drug Nalmefene earned mixed reactions, especially as the company is in the middle of lawsuits. Here's what you need to know.
-
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
-
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
-
Scientists are making progress toward a vaccine that could help protect against deadly overdoses.
-
A trustee with the DOJ filed a request for an “expedited stay” in order to prevent the initiation of the bankruptcy plan.
-
The Sacklers did not admit to any wrongdoing and have never been charged directly for the issue. Still, Purdue Pharma has pleaded guilty twice in its erroneous marketing efforts for OxyContin.
-
A Sackler family heir said in a court appearance that the family, which owns OxyContin drug maker Purdue Pharma, holds a “moral responsibility” to lend its help in combating the U.S. opioid crisis but noted it will not give billions of dollars to a legal settlement unless broad legal protections ...
-
The move by the 15 states' attorneys general comes about a month ahead of a court hearing set for Aug. 5.
-
Purdue Pharma L.P. Files Broadly Supported Plan of Reorganization
3/16/2021
Purdue Pharma L.P. filed a Chapter 11 plan of reorganization and a related disclosure statement in the United States Bankruptcy Court for the Southern District of New York.
-
In their first appearance in years, the notorious Sackler family, who previously headed OxyContin maker Purdue Pharma, apologized to victims of the opioid crisis but stopped short of admitting personal responsibility during a nearly four-hour grilling from the U.S. House Oversight and Reform Comm...
-
Days after Purdue Pharma reached a combined $8.4 billion criminal and civil settlement with the U.S. Department of Justice, the OxyContin drugmaker pleaded guilty to three criminal charges to resolve its role in the ongoing opioid crisis in the United States.
-
A settlement valued at $8.34 billion was reached between Purdue Pharma and the Justice Department on Tuesday, which required the drug company to plead guilty to three felonies related to its marketing and distribution of OxyContin.